X. Wang, Y. Chen, X. Zhang, Y. Chen, C. Tan, Y. Wang, J. Ding, L.-H. Meng and C. YangDiscovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo 2,1- f 1,2,4 triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors
发布时间：2020-07-20
点击次数：
发表刊物：Cancer Research
第一作者：H, Xiang
卷号：78
期号：13
是否译文：否
发表时间：2018-01-01
上一条： H. Xiang, J.-A. Xiao, P.-J. Xia, J.-J. Wang, X. Chen and H. YangSelectfluor-Triggered Tandem Cyclization of o-Hydroxyarylenaminones To Access Difluorinated 2-Amino-Substituted Chromanones
下一条： X. Wang, Y. Chen, X. Zhang, Y. Chen, C. Tan, Y. Wang, J. Ding, L.-H. Meng and C. YangDiscovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo 2,1- f 1,2,4 triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors